Author of 1 Presentation
SS 1.10 - CT and MRI features of non-cirrhotic portal fibrosis in comparison with liver cirrhosis: emphasis on focal hepatic lesions (ID 632)
Abstract
Purpose
To describe CT and MRI features of non-cirrhotic portal fibrosis (NCPF) in comparison to liver cirrhosis (LC), and to describe the characteristics of focal hepatic lesions detected in NCPF.
Material and methods
In this retrospective case-control study, 43 patients with pathologically proven NCPF (24 men; mean age, 50.7 years) from 2005 to 2018 were included. The control group with pathologically proven LC consisted of 129 patients (97 men; mean age, 51.7 years) matched with liver function. We evaluated the presence of liver surface nodularity and grades of portal hypertension, and compared them between the two groups using generalized linear mixed model. In addition, the presence and characteristics of focal hepatic lesions detected in NCPF were analyzed.
Results
Most patients with NCPF (36/43, 83.7%) showed no liver surface nodularity, while the majority of patients with LC (115/129, 89.2%) showed nodularity (P < 0.001). Grade 2 or 3 portal hypertension was significantly higher in the NCPF group than in the LC group (P ≤ 0.003). In the NCPF group, six patients (14.0%) had at least one focal hepatic lesions with arterial hyperenhancement. The most common pathologic diagnosis (4/6, 66.7%) was focal nodular hyperplasia (FNH). No malignant lesion was detected during the follow-up period (mean, 60.7 months).
Conclusion
In patients with portal hypertension, the absence of liver surface nodularity with higher grade portal hypertension is a suggestive feature of NCPF rather than LC. Benign focal lesions, most commonly FNH, were commonly accompanied in NCPF.
Presenter of 1 Presentation
SS 1.10 - CT and MRI features of non-cirrhotic portal fibrosis in comparison with liver cirrhosis: emphasis on focal hepatic lesions (ID 632)
Abstract
Purpose
To describe CT and MRI features of non-cirrhotic portal fibrosis (NCPF) in comparison to liver cirrhosis (LC), and to describe the characteristics of focal hepatic lesions detected in NCPF.
Material and methods
In this retrospective case-control study, 43 patients with pathologically proven NCPF (24 men; mean age, 50.7 years) from 2005 to 2018 were included. The control group with pathologically proven LC consisted of 129 patients (97 men; mean age, 51.7 years) matched with liver function. We evaluated the presence of liver surface nodularity and grades of portal hypertension, and compared them between the two groups using generalized linear mixed model. In addition, the presence and characteristics of focal hepatic lesions detected in NCPF were analyzed.
Results
Most patients with NCPF (36/43, 83.7%) showed no liver surface nodularity, while the majority of patients with LC (115/129, 89.2%) showed nodularity (P < 0.001). Grade 2 or 3 portal hypertension was significantly higher in the NCPF group than in the LC group (P ≤ 0.003). In the NCPF group, six patients (14.0%) had at least one focal hepatic lesions with arterial hyperenhancement. The most common pathologic diagnosis (4/6, 66.7%) was focal nodular hyperplasia (FNH). No malignant lesion was detected during the follow-up period (mean, 60.7 months).
Conclusion
In patients with portal hypertension, the absence of liver surface nodularity with higher grade portal hypertension is a suggestive feature of NCPF rather than LC. Benign focal lesions, most commonly FNH, were commonly accompanied in NCPF.